In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Mediwound, with a price target of $25.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Josh Jennings has given his Buy rating due to a combination of factors tied to both short‑term disruptions and long‑term growth drivers. He views the weak fourth‑quarter results as largely the product of a temporary U.S. government shutdown that delayed contract activity, while noting that the company still exited the year with a solid cash position and better‑than‑expected bottom‑line results.
He also highlights reaffirmed multi‑year revenue guidance that points to strong growth through 2028, underpinned by ongoing BARDA and Department of Defense contracts and the scaling of NexoBrid. With a major manufacturing expansion set to multiply NexoBrid capacity and support margin improvement, alongside the anticipated launch contribution from EscharEx later in the decade, Jennings sees a compelling path for revenue acceleration and profitability, supporting his Buy recommendation.
According to TipRanks, Jennings is a 4-star analyst with an average return of 4.3% and a 49.10% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Abbott Laboratories.
In another report released yesterday, Craig-Hallum also maintained a Buy rating on the stock with a $0.00 price target.